Vanta Bioscience (540729)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹51.45 |
| Market Cap | ₹33.1 Cr |
| P/E Ratio | 0 |
| ROCE | -11.58% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | 12.08% |
| Debt/Equity | — |
| Sales Growth | -70.87% |
| 52-Week Range | ₹14.71 — ₹51.45 |
| Sector | Healthcare Services |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
When I look at Vanta Bioscience, I am reminded of Graham's dictum: price is what you pay, value is what you get. At ₹51.45, the market cap is ₹33 crore, yet I have almost no tangible facts to anchor the other side of that equation. The latest quarter shows sales of ₹0 crore and a net loss of ₹2 crore. Sales growth is -70.87%. A business with no revenue and a negative bottom line is not an investment; it is a call option. Mr. Market has already pushed the stock to its 52-week high of ₹51.45 after trading as low as ₹14.71, but a rising price does not create value. With ROCE at -11.58%, the enterprise is destroying capital, not compounding it. The so-called profit growth of 12.08% is meaningless from a loss-making level. Book value, promoter holding and debt-to-equity are all blank; without these numbers I cannot compute a Graham-style safety cushion. The Piotroski score of 5/9 at least suggests the financial condition isn't as poor as it could be, but that is faint praise. There is no dividend to reward a patient shareholder. This is a speculative turnaround situation, not a proven compounder. I would need to see months of real revenue, evidence of a durable moat in healthcare research and analytics, and honest disclosure before I could consider allocating a rupee. For now, the only rational verdict is: too little information, no earnings visibility, and no margin of safety. I would rather wait for a good company at a fair price than chase a tiny, loss-making stock at its 52-week high. In Buffett's words, it's far better to be approximately right than precisely wrong; here, I am not sure I am even approximately informed.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer